Keyphrases
Tumor
71%
Non-small Cell Lung Cancer (NSCLC)
67%
Overall Survival
57%
Chemotherapy
49%
Confidence Interval
49%
Lung Cancer
41%
Breast Cancer
40%
Phase II Trial
34%
Clinical Trials
33%
Immune Checkpoint Inhibitors
31%
In Cancer
31%
Phase II Study
30%
Colorectal Cancer
29%
Metastatic Colorectal Cancer (mCRC)
29%
Electronic Cigarettes
28%
Older Adults
28%
Progression-free Survival
27%
Hazard Ratio
26%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
26%
Phase I Study
21%
Cancer Treatment
21%
Paclitaxel
20%
Targeted Therapy
20%
Programmed Death-ligand 1 (PD-L1)
20%
Cancer Patients
19%
Bevacizumab
19%
Head-and-neck Cancer
18%
Prostate Cancer
18%
High-risk Human Papillomavirus (HR-HPV)
18%
Solid Tumors
18%
United States
18%
Irinotecan
17%
Nivolumab
17%
Gemcitabine
16%
Oxaliplatin
16%
Clinical Outcomes
15%
Pancreatic Cancer
15%
T Cells
15%
Cisplatin
15%
Docetaxel
15%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
14%
Triple-negative Breast Cancer
14%
Phase I Trial
14%
Adverse Events
14%
5-fluorouracil (5-FU)
14%
Oncology
14%
Advanced Solid Tumors
14%
Radiation Therapy
14%
Cigarette
14%
Metastatic Breast Cancer
13%
Partial Response
13%
Gp96
13%
Adjuvant Therapy
13%
Radiotherapy
13%
Melanoma
13%
Malignancy
13%
Colon Cancer
13%
Antitumor Activity
13%
Systemic Therapy
13%
Carboplatin
12%
Inflammation
12%
Pembrolizumab
12%
Tumor Microenvironment
12%
Ovarian Cancer
12%
Risk Factors
12%
Cetuximab
12%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
Interferon-α (IFN-α)
12%
Tobacco
12%
Fluorouracil
12%
Tumor Cells
12%
Median Overall Survival
11%
Metastatic Disease
11%
Adjuvant Chemotherapy
11%
Response Rate
11%
Gene Expression
11%
Epidermal Growth Factor Receptor
11%
Breast Cancer Patients
11%
Liquid Biopsy
11%
Natural Killer Cells
11%
Lycopene
11%
Stable Disease
10%
Interleukin-2
10%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
10%
Disease Progression
10%
Objective Response Rate
10%
Small Cell Lung Cancer
10%
Randomized Trial
10%
CD8+ T Cells
10%
Interleukin-12 (IL-12)
10%
Dendritic Cells
10%
Tobacco Use
10%
Monoclonal Antibody
10%
Placebo
10%
Vascular Endothelial Growth Factor
10%
Circulating Tumor DNA (ctDNA)
10%
Leukemia
10%
High Risk
10%
Dose-limiting Toxicity
10%
Standard of Care
10%
Medicine and Dentistry
Malignant Neoplasm
100%
Neoplasm
94%
Breast Cancer
67%
Diseases
62%
Non Small Cell Lung Cancer
59%
Overall Survival
54%
Lung Cancer
48%
Cancer
37%
Biological Marker
35%
Immunotherapy
32%
Clinical Trial
32%
Oncology
29%
Colorectal Carcinoma
29%
Immune Checkpoint Inhibitor
26%
Progression Free Survival
25%
Metastatic Carcinoma
24%
Radiation Therapy
24%
Hazard Ratio
21%
Targeted Therapy
20%
Cancer Therapy
19%
Prostate Cancer
19%
Melanoma
18%
Nivolumab
18%
Adverse Event
18%
Pancreas Cancer
17%
Recurrent Disease
17%
Wart Virus
17%
Epidermal Growth Factor Receptor
17%
Cancer Cell
17%
Carcinogenesis
17%
Arm
15%
Colon Carcinoma
15%
Head and Neck Cancer
14%
Systemic Therapy
13%
Triple Negative Breast Cancer
13%
Solid Malignant Neoplasm
13%
Metastatic Colorectal Cancer
13%
T Cell
12%
Chemoradiotherapy
12%
Clear Cell Renal Cell Carcinoma
11%
Ovarian Cancer
11%
Prevalence
11%
Hepatocellular Carcinoma
11%
Ipilimumab
11%
Quality of Life
10%
Pancreas Adenocarcinoma
10%
Electronic Cigarette
10%
Liquid Biopsy
10%
Adjuvant Therapy
10%
Cancer Risk
10%
Pembrolizumab
10%
Lung
9%
Paclitaxel
9%
Non-Small Cell Lung Cancer
9%
Squamous Cell Carcinoma
9%
Adjuvant Chemotherapy
9%
Tyrosine-Kinase Inhibitor
9%
Odds Ratio
9%
Tumor Progression
9%
Fluorouracil
9%
Systematic Review
8%
Brain Metastasis
8%
Neoadjuvant Chemotherapy
8%
Head and Neck Squamous Cell Carcinoma
8%
Adenocarcinoma
8%
Phase II Trials
8%
Gemcitabine
8%
Cisplatin
8%
Small Cell Lung Cancer
8%
Gene Expression
8%
Meta-Analysis
8%
Infection
8%
Bevacizumab
8%
Next Generation Sequencing
8%
Combination Therapy
8%
COVID-19
8%
Programmed Death-Ligand 1
8%
Leukemia
7%
Neuroendocrine Tumor
7%
Metastatic Breast Cancer
7%
Randomized Controlled Trial
7%
Tumor Cell
7%
Dietary Pattern
7%
Programmed Cell Death
7%
Disease Free Survival
7%
Carboplatin
7%
Receptor
7%
Pooled Analysis
7%
Tumor Microenvironment
7%
In Vitro
7%
Immune-Related Adverse Events
7%
Circulating Tumor DNA
7%
Oxaliplatin
7%
Vasculotropin
7%
Proportional Hazards Model
6%
Oropharynx Carcinoma
6%
Tobacco Use
6%
Health Care Cost
6%
Connective Tissue Cancer
6%
Cytotoxic T-Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
96%
Neoplasm
94%
Chemotherapy
69%
Diseases
59%
Non Small Cell Lung Cancer
59%
Overall Survival
52%
Breast Cancer
43%
Clinical Trial
37%
Lung Cancer
36%
Progression Free Survival
33%
Biological Marker
33%
Solid Malignant Neoplasm
32%
Immunotherapy
28%
Adverse Event
27%
Colorectal Carcinoma
27%
Paclitaxel
24%
Metastatic Colorectal Cancer
23%
Immune Checkpoint Inhibitor
22%
Epidermal Growth Factor Receptor
22%
Fluorouracil
20%
Prostate Cancer
19%
Pharmacokinetics
19%
Colon Carcinoma
18%
Bevacizumab
18%
Phase II Trials
18%
Irinotecan
17%
Cisplatin
17%
Pancreas Cancer
17%
Carcinogenesis
16%
Gemcitabine
16%
Melanoma
15%
Docetaxel
15%
Oxaliplatin
14%
Chemoradiation Therapy
13%
Nivolumab
13%
Recurrent Disease
12%
Carboplatin
12%
Placebo
12%
Phase I Trials
12%
Human Papillomavirus
11%
Tumor Growth
11%
Combination Therapy
11%
Triple Negative Breast Cancer
11%
Cetuximab
10%
Head and Neck Cancer
10%
Ipilimumab
10%
Metastatic Breast Cancer
10%
Protein Tyrosine Kinase Inhibitor
10%
Vasculotropin
10%
Maximum Tolerated Dose
10%
Cytokine
10%
Renal Cell Carcinoma
10%
Liver Cell Carcinoma
9%
Folinic Acid
9%
Antitumor Activity
9%
Ovary Cancer
9%
Erlotinib
9%
Protein P53
9%
Pembrolizumab
8%
Neutropenia
8%
Small Cell Lung Cancer
8%
Monoclonal Antibody
8%
Receptor
8%
Squamous Cell Carcinoma
8%
Disease Exacerbation
8%
Inflammation
8%
Disease Free Survival
8%
Capecitabine
8%
Adenocarcinoma
8%
Prevalence
7%
Diarrhea
7%
Pancreas Adenocarcinoma
7%
Randomized Controlled Trial
7%
Leukemia
7%
Head and Neck Squamous Cell Carcinoma
7%
Monotherapy
6%
Phase III Trials
6%
Castration Resistant Prostate Cancer
6%
Infection
6%
Brain Metastasis
6%
Doxorubicin
6%
Randomized Clinical Trial
6%
Programmed Death 1 Ligand 1
6%
Cohort Study
6%
Interferon
6%
Treatment Group
6%
Trastuzumab
5%
Thyroid Cancer
5%
Tolerability
5%
Kidney Metastasis
5%
Cyclophosphamide
5%
Tumor Microenvironment
5%
Advanced Cancer
5%
Transitional Cell Carcinoma
5%
Interleukin 2
5%
Survival Rate
5%
Histone Deacetylase Inhibitor
5%
Side Effect
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Neuroendocrine Tumor
5%